Jennifer Cornett
Papers
2
Total Citations
192
H-Index
2
About
Jennifer Cornett is a pioneering researcher in regenerative medicine, with a primary focus on cell-based therapies for Duchenne muscular dystrophy (DMD). Her landmark contributions center on myoblast transfer therapy (MTT), an experimental treatment designed to restore muscle function in boys with this devastating genetic disorder. In her seminal 1992 study, cited 106 times, Cornett demonstrated the feasibility, safety, and efficacy of injecting five billion normal myoblasts into the lower limbs of 21 DMD boys aged 6–14, marking a critical Phase II trial. She expanded this work in a 1993 study (86 citations), treating 32 boys—half of whom were nonambulatory—through 48 precise injections, further validating MTT’s potential to strengthen weakened muscles. Cornett’s research has been instrumental in advancing cell transplantation as a therapeutic strategy for muscular dystrophy, laying groundwork for future gene and cell therapies. Her rigorous clinical trials have shaped the field’s understanding of dose, delivery, and patient selection, earning her recognition as a key figure in translational neuromuscular medicine. For students and researchers, Cornett’s work exemplifies the challenges and promise of bringing experimental cell therapies from bench to bedside.
Research Focus
Key Achievements
Top Papers
- 1
- 2